Let’s get novel for rare oncology
Our late-stage rare oncology programs have the potential to be best-in-class treatments for patients with two devastating diseases: desmoid tumors and neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).
Let’s dig into BCMA combinations
in multiple myeloma
Our gamma secretase inhibitor, nirogacestat, is being advanced as a potential cornerstone of BCMA combination therapy across modalities in collaboration with industry leaders. In preclinical models, nirogacestat has been shown to increase levels of membrane-bound BCMA and reduce levels of soluble BCMA, thereby enhancing the activity of BCMA-targeted therapies. Our goal is to meaningfully improve clinical outcomes for patients with multiple myeloma.
Let’s take on biomarker-defined metastatic solid tumors
We are using a precision oncology approach to evaluate investigational medicines for highly-prevalent, biomarker-defined metastatic cancers in monotherapy and combination therapy studies. If successful, our programs could potentially address more than one-third of solid tumor patients.
Our values drive us
We take caring very seriously. We care about our patients deeply, intensely, and relentlessly. Every day, we care for patients by working harder to develop solutions others haven’t.
Ambition Without Ego
We exist to ignite the power of promising science to unleash new possibilities for patients. To make this audacious ambition a reality, we must not let personal pride, empty rhetoric, or ego get in the way.
Think Deeply, Act Quickly
Our team is measured, comprehensive, and thoughtful about every move we make, but we’re also driven by a sense of urgency because we know that patients are waiting. We delicately and expertly balance thinking and acting while always upholding our commitment to the highest standards of ethics and integrity.
Good Enough is Never Enough
“Good enough” is never enough for the patients and families counting on us. That’s why we constantly push ourselves to become smarter, better, and faster in pursuit of our ambition.
In It Together
We’re a team, first and foremost. Each and every SpringWorker is all in with their coworkers, partners, and patients. We do our best work when we all get together, hurling jokes and big ideas, and collectively making it happen.
I enjoy working at SpringWorks because everyone is driven to pursue new possibilities and push themselves - and our company - to be better.Michelle PatelHead of Commercial Operations
Join the Pursuit
We give it our all every day because we believe targeted oncology is the best way to change the outlook for people with cancer. The answers are waiting. Let’s go find them together.